Study guide
11.2 Monitoring Visits (SIV, IMV, COV)
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
11.2 Monitoring Visits (SIV, IMV, COV)
Key Takeaways Explain This Topic AI
The Site Initiation Visit (SIV) prepares the site for enrollment and requires signed CTAs and IRB approval.
Interim Monitoring Visits (IMVs) involve 100% informed consent review, SDV/SDR, and IP accountability checks.
The Close-Out Visit (COV) occurs when all subjects have completed the study and all data is locked.
Last updated: October 2026
11.2 Monitoring Visits (SIV, IMV, COV)
Clinical trial monitoring occurs across the entire lifecycle of a study. The Clinical Research Associate (CRA) conducts distinct types of visits to initiate, oversee, and conclude the trial at the site level. Understanding the specific goals, required attendees, and necessary preparations for the Site Initiation Visit (SIV), Interim Monitoring Visit (IMV), and Close-Out Visit (COV) is essential for a Clinical Research Coordinator (CRC).
Site Initiation Visit (SIV)
The Site Initiation Visit marks the transition from study start-up to active enrollment. It is the final step before a site is authorized to screen and enroll subjects.
Prerequisites for an SIV
Before the sponsor will schedule an SIV, several regulatory and contractual milestones must be met:
The Clinical Trial Agreement (CTA) and budget must be fully executed.
The Institutional Review Board (IRB) must have approved the protocol, Informed Consent Form (ICF), and patient-facing materials.
All essential documents must be collected (e.g., Form FDA 1572, Financial Disclosure Forms, CVs, medical licenses).
The Investigational Product (IP) and necessary study supplies (e.g., lab kits, EDC access) must be shipped or ready to ship.
SIV Attendees and Agenda
The SIV is a comprehensive training session. Required attendees typically include the Principal Investigator (PI), CRCs, sub-investigators, and the investigational pharmacist.
During the SIV, the CRA will cover:
Protocol Review: A detailed walk-through of the study design, inclusion/exclusion criteria, primary endpoints, and visit schedule.
Safety Reporting: Review of the procedures and timelines for reporting Adverse Events (AEs) and Serious Adverse Events (SAEs).
Investigational Product Management: Review of the Pharmacy Manual, covering IP receipt, storage requirements, preparation, dispensing, and accountability.
Systems Training: Demonstration of the Electronic Data Capture (EDC) system, Interactive Web Response System (IWRS) for randomization, and electronic Patient-Reported Outcomes (ePRO) devices.
Regulatory Review: A final check of the Investigator Site File (ISF) to ensure all documents are present and correctly filed.
Once the SIV is completed and any outstanding action items are resolved, the sponsor will issue an official "Site Activation Letter," giving the site the green light to begin consenting subjects.
Interim Monitoring Visit (IMV)
Interim Monitoring Visits (IMVs) are the most frequent type of monitoring visit. Their purpose is to provide ongoing oversight to ensure the site is conducting the trial safely, ethically, and in compliance with the protocol and GCP.
Frequency of IMVs
The frequency of IMVs depends on the sponsor's monitoring plan. High-enrolling sites, early-phase trials (Phase I/II), or trials with complex protocols require more frequent IMVs (e.g., every 4-6 weeks). Trials utilizing Risk-Based Monitoring (RBM) may have fewer on-site IMVs, relying instead on centralized data review.
Key Activities During an IMV
During an IMV, the CRA will systematically review trial conduct across several domains:
1. Informed Consent Review
This is the most critical element of the IMV. The CRA will perform a 100% review of all ICFs signed since the last visit. They will check that the correct, IRB-approved version was used, all required signatures and dates (from the participant and the person who conducted the consent discussion) are present and precede any study procedure, and the consent process was adequately documented in the source notes.
2. Source Data Verification/Review (SDV/SDR)
The CRA will review subject source documents and compare them to the data entered into the EDC. They will look for:
Missing data or unreported adverse events.
Out-of-window study visits or missed procedures.
Concomitant medications that are prohibited by the protocol.
Proper PI oversight (e.g., PI signatures on clinically significant lab results).
3. Investigational Product Accountability
The CRA will visit the pharmacy or IP storage area to:
Verify temperature logs to ensure IP stability.
Count the physical IP inventory and compare it against the dispensing logs (IVRS/IWRS).
Ensure returned IP from subjects is accurately documented and quarantined for destruction or return to the sponsor.
4. Regulatory Binder (ISF) Review
The CRA ensures that new documents (e.g., protocol amendments, updated investigator brochures, recent IRB continuing reviews) have been filed correctly and that the Delegation of Authority log is current.
IMV Follow-Up
At the conclusion of the IMV, the CRA meets with the PI and CRC to discuss findings. Following the visit, the CRA issues a Follow-Up Letter detailing action items (e.g., resolving specific EDC queries, obtaining a missing signature, re-training staff on a protocol amendment). The CRC must address these action items promptly.
Close-Out Visit (COV)
The Close-Out Visit (COV) occurs at the end of the trial to officially formally close the site.
When Does a COV Occur?
A COV is scheduled only when:
All subjects at the site have completed all protocol-required visits (or terminated early).
All source data has been verified and all EDC queries are resolved.
The database is locked (or the site's portion of the database is ready for lock).
Key Activities During a COV
The COV focuses on final reconciliation and archiving:
Final IP Reconciliation: All remaining unused and used IP must be destroyed on-site (if permitted by the sponsor and site SOPs) or shipped back to the sponsor. The CRA will collect the final IP accountability logs.
Final ISF Review: The CRA ensures the regulatory binder is complete. All logs (Delegation of Authority, Site Visit Log) must be finalized, signed, and dated by the PI.
Archiving Instructions: The CRA will provide instructions on how and where to archive the study documents. Per ICH E6(R3) 2.12.12, essential records are retained for the required period under applicable regulatory requirements or until the sponsor informs the site they are no longer needed, whichever is longest.
IRB Notification: The site must submit a final report to the IRB to officially close the study locally.
A successful COV requires the same level of preparation as an SIV or IMV. Once the COV is complete, the site's involvement in the clinical trial officially concludes.